Inhibition of cyclin-dependent kinase-2 induces apoptosis in human diffuse large b-cell lymphomas

Cell Cycle

Volumn 6, Issue 23, 2007, Pages 2982-2989

  Faber, Anthony C ^a   Chiles, Thomas C ^a  

^a BOSTON COLLEGE   (United States)

Author keywords

Apoptosis; Cdk2; Cell cycle; CVT 313; Diffuse large B cell lymphoma; Mcl 1

Indexed keywords

CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; PROTEIN MCL 1; RETINOBLASTOMA PROTEIN; RNA POLYMERASE II; SMALL INTERFERING RNA; 2 BIS(2 HYDROXYETHYL)AMINO 9 ISOPROPYL 6 (4 METHOXYBENZYLAMINO)PURINE; CDK2 PROTEIN, HUMAN; MCL1 PROTEIN; PROTEIN BCL 2; PURINE DERIVATIVE; TUMOR PROTEIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; B CELL LYMPHOMA; CANCER CELL CULTURE; CANCER INHIBITION; CARCINOGENESIS; CELL CYCLE REGULATION; CELL SURVIVAL; CONTROLLED STUDY; ENZYME INHIBITION; HUMAN; HUMAN CELL; LARGE CELL LYMPHOMA; RNA INTERFERENCE; DOWN REGULATION; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; PATHOLOGY; PHOSPHORYLATION; PHYSIOLOGY;

APOPTOSIS; CYCLIN-DEPENDENT KINASE 2; DOWN-REGULATION; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; NEOPLASM PROTEINS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-BCL-2; PURINES; RNA, SMALL INTERFERING;

EID: 85011942155     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.6.23.4994     Document Type: Article

References (47)

1. Sherr CJ, Roberts JM. Living with or without cyclins and cyclin-dependent kinases. Genes Dev 2004; 18:2699-711.
2. Morgan DO. Cyclin-dependent kinases: Engines, clocks, and microprocessors. Annu Rev Cell Dev Biol 1997; 13:261-91.
3. Sherr CJ, Roberts JM. CDK inhibitors: Positive and negative regulators of G1-phase progression. Genes Dev 1999; 13:1501-12.
4. Harbour JW, Luo RX, Dei Santi A, Postigo AA, Dean DC. Cdk phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G1. Cell 1999; 98:859-69.
5. Lundberg AS, Weinberg RA. Functional inactivation of the retinoblastoma protein requires sequential modification by at least two distinct cyclin-cdk complexes. Mol Cell Biol 1998; 18:753-61.
6. van den Huevel S, Harlow E. Distinct roles for cyclin-dependent kinases in cell cycle control. Science 1993; 5142:2050-4.
7. Shapiro GI. Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol 2006; 24:1770-83.
8. Malumbres M, Barbacid M. To cycle or not to cycle: A critical decision in cancer. Nat Rev Cancer 2001; 1:222-31.
9. Merup M, Juliusson G, Wu X, Jansson M, Stellan B, Rasool O, Röijer E, Stenman G, Gahrton G, Einhorn S. Amplification of multiple regions of chromosome 12, including 12q13-15, in chronic lymphocytic leukaemia. Eur J Haematol 1997; 20:155-60.
10. Dierlamn J, Wlodarska I, Michaux L, Vermeesch JR, Meeus P, Stul M, Criel A, Verhoef G, Thomas J, Delannoy A, Louwagie A, Cassiman JJ, Mecucci C, Hagemeijer A, Van den Berghe H. FISH identities different types of duplications with 12q13-15 as the commonly involved segment in B-cell lymphoproliferative malignancies characterized by partial trisomy 12. Genes Chrom Cancer 1997; 20:155-66.
11. Bea S, Ribas M, Hernandez JM, Bosch F, Pinyol M, Hernandez L, Garcia JL, Flores T, Gonzalez M, Lopez-Guillermo A, Piris MA, Cardesa A, Montserrat E, Miro R, Campo E. Increased number of chromosomal imbalances and high-level DNA amplifications in mantle cell lymphoma are associated with blastoid variants. Blood 1999; 93:4365-74.
12. Hough RE, Gospel JR, Alcock HE, Hancock BW, Lorigan PC, Hammond DW. Copy number gain at 12q12-14 may be important in the transformation from follicular lymphoma to diffuse large B cell lymphoma. Brit J of Cancer 2001; 84:499-503.
13. Martinez-Climent JA, Alizadeh AA, Segraves R, Blesa D, Rubio-Moscardo F, Albertson DG, Garcia-Conde J, Dyer MJ, Levy R, Pinkel D, Lossos IS. Transformation of follicular lymphoma to diffuse large-cell lymphoma is associated with a heterogenous set of DNA copy number and gene expression alterations. Blood 2003; 101:3109-17.
14. Al-Assar O, Rees-Unwin KS, Menasce LP, Hough RE, Goepel JR, Hammond DW, Hancock BW. Transformed diffuse large B-cell lymphomas with gains of the discontinous 12q12-14 amplicon display concurrent deregulation of CDK2, CDK4 and GADD153 genes. Brit Journ of Haem 2006; 133:612-21.
15. Bea S, Zettl A, Wright G, Salaverria I, Jehn P, Moreno V, Burek C, Ott G, Puig X, Yang L, Lopez-Guillermo A, Chan WC, Greiner TC, Weisenburger DD, Armitage JO, Gascoyne RD, Connors JM, Grogan TM, Braziel R, Fisher RI, Smeland EB, Kvaloy S, Holte H, Delabie J, Simon R, Powell J, Wilson WH, Jaffe ES, Montserrat E, Muller-Hermelink HK, Staudt LM, Campo E, Rosenwald A. Lymphoma/leukemia molecular profiling project: Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction. Blood 2005; 106:3183-90.
16. Wang X, Gorospe M, Huang Y, Holbrook NJ. P27kip1 overexpression causes apoptotic death of mammalian cells. Oncogene 1997; 15:2991-7.
17. 2 roles for cdk2 revealed by inducible expression of a dominant-negative mutant in human cells. Mol Cell Biol 2001; 21:2755-66.
18. McCormick F, Tetsu O. Proliferation of cancer cells despite CDK2 inhibition. Cancer Cell 2003; 3:233-45.
19. Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML, Delsol G, De Wolf-Peeters C, Falini B, Gatter KC, et al. A revised European-American classification of lymphoid neoplasm: A proposal from the International Lymphoma Study Group. Blood 1994; 84:1361-92.
20. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, Boldrick JC, Sabet H, Tran T, Yu X, Powell JI, Yang L, Marti GE, Moore T, Hudson Jr J, Lu L, Lewis DB, Tibshirani R, Sherlock G, Chan WC, Greiner TC, Weisenburger DD, Armitage JO, Warnke R, Levy R, Wilson W, Grever MR, Byrd JC, Botstein D, Brown PO, Staudt LM. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403:503-11.
21. Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, Gascoyne RD, Muller-Hermelink HK, Smeland EB, Giltnane JM, Hurt EM, Zhao H, Averett L, Yang L, Wilson WH, Jaffe ES, Simon R, Klausner RD, Powell J, Duffey PL, Longo DL, Greiner TC, Weisenburger DD, Sanger WG, Dave BJ, Lynch JC, Vose J, Armitage JO, Montserrat E, Lopez-Guillermo A, Grogan TM, Miller TP, LeBlanc M, Ott G, Kvaloy S, Delabie J, Holte H, Krajci P, Stokke T, Staudt LM. Lymphoma/Leukemia Molecular Profiling Project: The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002; 346:1937-47.
22. Savage KJ, Monti S, Kutok JL, Cattoretti G, Neuberg D, De Leval L, Kurtin P, Dal Cin P, Ladd C, Feuerhake F, Aguiar RC, Li S, Salles G, Berger F, Jing W, Pinkus GS, Habermann T, Dalla-Favera R, Harris NL, Aster JC, Golub TR, Shipp MA. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood 2003; 102:3871-9.
23. Rao PH, Houldsworth J, Dyomina K, Murty VV, Reuter VE, Motzer RJ, Bosl GJ, Chaganti RS. Chromosomal and gene amplification in diffuse large B-cell lymphoma. Blood 1998; 92:234-40.
24. Losso IS, Levy R. Higher-grade transformation of follicle center lymphoma is associated with somatic mutation of the 5′ noncoding regulatory region of the BCL-6 gene. Blood 2000; 96:635-9.
25. Matolcsy A, Casali P, Warnke RA, Knowles DM. Morpholic transformation of follicular lymphoma is associated with somatic mutation of the translocated Bcl-2 gene. Blood 1996; 88:3937-44.
26. Lee JT, Innes Jr DJ, Williams ME. Sequential bcl-2 and c-myc oncogene rearrangements associated with the clinical transformation of follicular lymphoma. J Clin Invest 1989; 84:1454-9.
27. Brooks EE, Gray NS, Joly A, Kerwar SS, Lum R, Mackman RL, Norman TC, Rosete J, Rowe M, Schow SR, Schultz PG, Wang X, Wick MM, Shiffman D. CVT-313, a specific and potent inhibitor of CDK2 that prevents neointimal proliferation. J Biol Chem 1997; 29207-11.
28. Cisek LJ, Corden JL. Phosphorylation of RNA polymerase by the murine homologue of the cell cycle control protein cdc2. Nature 1989; 339:679-84.
29. Mehra S, Messner M, Minden M, Chaganti RSK. Molecular cytogenetic characterization of non-hodgkin lymphoma cell lines. Genes Chrom and Cancer 2002; 33:225-34.
30. Abbas T, Jha S, Sherman NE, Dutta A. Autocatalytic phosphorylation of CDK2 at the activating Thr160. Cell Cycle 2007, (in press).
31. Knudsen ES, Wang JY. Differential regulation of retinoblastoma protein function by specific Cdk phosphorylation sites. J of Biol Sci 1996; 271:8313-20.
32. Gojo I, Zhang B, Fenton RG. The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in multiple myeloma cells through transcriptional repression and down-regulation of MCL-1. Clin Cancer Res 2002; 8:3527-38.
33. Raje N, Kumar S, Hideshima T, Roccaro A, Ishitsuka K, Yasui H, Shiraishi N, Chauhan D, Munshi NC, Green SR, Anderson KC. Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity down-regulation of Mcl-1 in multiple myeloma. Blood 2006; 106:1042-7.
34. Gao N, Kramer L, Rahmani M, Dent P, Grant S. The three-substituted indolinone cyclin-dependent kinase 2 inhibitor 3-[1-(3H-imidazol-4-yl)-meth-(Z)- ylidene]-5-methoxy-1,3-dihydro-indol-2-one(SU9516) kills human leukemia cells via down-regulation of Mcl-1 through a transcriptional mechanism. Molecular Pharmacology 2006; 70:645-5.
35. Deng L, Ammosova T, Pumfery A, Kashanchi F, Nekhai S. HIV-1 Tat interaction with RNA polymerase II C-terminal domain (CTD) and a dynamic association with CDK2 induce CTD phosphorylation and transcription from HIV-1 promoter. J Biol Chem 2002; 277:33922-9.
36. The Non-Hodgkin's Lymphoma Classification Project: A clinical evaluation of the international lymphoma study group classification of non-Hodgkin's lymphoma. Blood 1997; 89:3909-18.
37. Demetrick DJ, Xhang H, Beach DH. Chromosomal mapping of human CDK2, CDK4, and CDK5 cell cycle kinase genes. Cytogenet Cell Genet 1994; 66:72-4.
38. Cai D, Latham Jr VM, Zhang X, Shapiro GI. Combined depletion of cell cycle and transcriptional cyclin-dependent kinase activities induces apoptosis in cancer cells. Cancer Res 2006; 66:9270-80.
39. Kitada S, Zapata JM, Andreeff M, Reed JC. Protein kinase inhibitors flavopiridol and 7-hydroxy-staurosporine down-regulate antiapoptosis proteins in B-cell chronic lymphocytic leukemia. Blood 2000; 96:393-7.
40. Lane ME, Yu B, Rice A, Lipson KE, Liang C, Sun L, Tang C, McMahon G, Pestell RG, Wadler S. A novel cdk2-selective inhibitor, SU9516, induces apoptosis in colon carcinoma cells. Cancer Res 2001; 16:6170-7.
41. Blagosklonny MV. Flavopiridol, an inhibitor of transcription: Implications, problems and solutions. Cell Cycle 2004; 12:1537-42.
42. Zhang B, Gojo I, Fenton RG. Myeloid cell factor-1 is a critical survival factor for multiple myeloma. Blood 2002; 99:1885-93.
43. Nijhawan D, Fang M, Traer E, Zhong Q, Gao W, Du F, Wang X. Elimination of Mcl-1 is required for the initiation of apoptosis following ultraviolet irradiation. Genes Dev 2003; 17:1475-86.
44. Kashkar H, Haefs C, Shin H, Hamilton-Dutoit SJ, Salvesen GS, Kronke M, Jurgensmeier JM. XIAP-mediated caspase inhibition in Hodgkin's lymphoma-derived B cells. J Exp Med 2003; 198:341-7.
45. Uddin S, Hussain AR, Sirai AK, Manogaran PS, Al-Jomah NA, Moorji A, Atizado V, Al-Dayel F, Belgaumi A, El-Solh H, Ezzat A, Bavi P, Al-Kuraya KS. Role of phosphatidylinositol 3′-kinase/AKT pathway in diffuse large B-cell lymphoma survival. Blood 2006; 108:4178-86.
46. Schimmer AD, Welsh K, Pinilla C, Wang Z, Krajewska M, Bonneau MJ, Pedersen IM, Kitada S, Scott FL, Bailly-Maitre B, Glinsky G, Scudiero D, Sausville E, Salvesen G, Nefzi A, Ostresh JM, Houghten RA, Reed JC. Small-molecule antagonists of apoptosis suppressor XIAP exhibit broad antitumor activity. Cancer Cell 2004; 5:25-35.
47. Marshall NF, Peng J, Xie Z, Price DH. Control of RNA polymerase II elongation potential by a novel carboxyl-terminal domain kinase. J Biol Chem 1996; 271:27176-83.